Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179138 | 0.88 | MEN1 (0.37) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL1179625 | 0.86 | KDM4E (0.42) | HCRTR1HCRTR2MEN1KMT2ACRHR1 | |
| SCHEMBL1179517 | 0.84 | ESR1 (0.36) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL1179165 | 0.84 | LMNA (0.33) | MEN1KMT2AALDH1A1HTT | |
| SCHEMBL1179265 | 0.81 | HCRTR1 (0.35) | HCRTR1HCRTR2MEN1KMT2AALDH1A1 | |
| SCHEMBL1179068 | 0.81 | MEN1 (0.36) | HCRTR1HCRTR2MEN1KMT2ACRHR1 | |
| SCHEMBL1179729 | 0.79 | HRH4 (0.33) | MEN1KMT2A | |
| SCHEMBL1179543 | 0.76 | HCRTR1 (0.41) | HCRTR1HCRTR2ALDH1A1HTT | |
| SCHEMBL12870911 | 0.76 | CRHR1 (0.46) | HCRTR1HCRTR2CRHR1ALDH1A1HTT | |
| SCHEMBL1425691 | 0.74 | GAA (0.36) | MEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | HCRTR1 4338/4885HCRTR2 4282/4885MEN1 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.